Life sciences & healthcare
Life sciences & healthcare
Bridgepoint Growth
Advised on Bridgepoint's investment in Identicare, a UK-based pet microchipping and pet owner-focused services company. Bridgepoint acquired Identicare from Animalcare Group, the international animal health business. This investment brings significant experience to support Identicare with its strategy to grow across all areas of microchipping, registration services and real-time support for pet owners.
UK
BioMaxima S.A
We helped BioMaxima on the transfer of the company's listing from NewConnect to the main trading floor of the Warsaw Stock Exchange. It was the first debut on the WSE's main market in 2022. BioMaxima is a Polish manufacturer of microbiological media, reagents and equipment for in vitro diagnostics, and it exports its products to more than 60 countries.
Poland
Placid0
Advised Placid0 on its acquisition by innovative eyecare brand, WALDO. Placid0 has created EASY, an eye assessment system mobile application. The technology addresses all aspects of eye health and the acquisition is the next step in WALDO's goal of making eyecare an essential part of everyday life, with both companies and the app focused on closing the data gap between patients and their eye care professionals.
UK
Theramex
Advised the management team of Theramex, the leading global specialty pharmaceuticals company focused on women’s health, on its sale by CVC Capital Partners VI (CVC) to global investment firms Carlyle and PAI Partners. The sale enables Theramax to expand its diverse suite of products across existing and adjacent therapeutic areas and accelerate international expansion.
Formycon
Advised Formycon AG on its strategic partnership with ATHOS KG, the family office of the Strüngmann family. The partnership meant Formycon and ATHOS KG merged their development activities of biosimilars, with Formycon also acquiring full rights to FYB202, a biosimilar candidate for Stelara, a 50% stake in FYB201, a biosimilar candidate for Lucentis, and the operational development unit Bioeq GmbH. A multi-practice team led this significant €650 million transaction.
Germany
Balderton Capital
Advised Balderton Capital on a €50 million Series B funding round in Avi Medical. By the end of 2022, Avi's founders planned to operate 20 Avi Medical practices in Munich, Hamburg and Berlin.
Germany
Inflexion
Advised Inflexion on its substantial investment into contract development and manufacturing organisation Upperton Pharma Solutions, which specialises in particle engineering for the pharmaceutical industry. The investment from Inflexion, which comes alongside the founder's own investment, will support Upperton in expanding its manufacturing, operations and services facilities.
UK
Eurofins Scientific
Advised Eurofins Scientific on the sale of its testing business to Stirling Square Capital Partners for €220m. Eurofins Scientific is a global leader in food and bioanalytical testing.
UK, US, China
Daye
Advised health and wellness start-up Daye on its Series A funding round. Daye is focused on bridging the gender gap in medical research and shifting the balance towards people having more control over their reproductive health.
UK
Apollo Therapeutics
Advised on the $226.5 million Series C fundraising of Apollo Therapeutics, a Cambridge-headquartered biopharma company. With this financing, Apollo will further fund its drug discovery and development activities based on breakthroughs in basic medical research made at its partner institutions.
Azenta, Inc
Advised Azenta on its acquisition of B Medical Systems for €410 million. Based in Massachusetts and listed on Nasdaq, Azenta is a leading provider of life sciences solutions worldwide. B Medical Systems is a manufacturer and global provider of products including vaccine transport cold chain equipment, medical refrigeration, and blood management solutions, and is based in Luxembourg.
UK
Shield Therapeutics plc
Advised Shield Therapeutics, an AIM-listed commercial stage specialty pharmaceutical company, on three simultaneous complex transactions including its transformational collaboration agreement with global healthcare company Viatris Inc.
UK, US
BioMaxima S.A
We helped BioMaxima on the transfer of the company's listing from NewConnect to the main trading floor of the Warsaw Stock Exchange. It was the first debut on the WSE's main market in 2022. BioMaxima is a Polish manufacturer of microbiological media, reagents and equipment for in vitro diagnostics, and it exports its products to more than 60 countries.
Life sciences
Poland
Inflexion
Advised Inflexion on its substantial investment into contract development and manufacturing organisation Upperton Pharma Solutions, which specialises in particle engineering for the pharmaceutical industry. The investment from Inflexion, which comes alongside the founder's own investment, will support Upperton in expanding its manufacturing, operations and services facilities.
Life sciences
UK
Apollo Therapeutics
Advised on the $226.5 million Series C fundraising of Apollo Therapeutics, a Cambridge-headquartered biopharma company. With this financing, Apollo will further fund its drug discovery and development activities based on breakthroughs in basic medical research made at its partner institutions.
Azenta, Inc
Advised Azenta on its acquisition of B Medical Systems for €410 million. Based in Massachusetts and listed on Nasdaq, Azenta is a leading provider of life sciences solutions worldwide. B Medical Systems is a manufacturer and global provider of products including vaccine transport cold chain equipment, medical refrigeration, and blood management solutions, and is based in Luxembourg.
Life sciences
UK
